Wednesday, July 16, 2025 7/16/2025

Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic

Award Number: U19AI077289
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/27/2008
PERIOD OF PERFORMANCE END DATE: 05/31/2014

Group Awards By:

View Award Description

Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic - Two new prototype microbicide products will be developed: one based on an intravaginal ring delivery system and one on a bioresponsive (smart) gel delivery vehicle. Both products will be designed to function with the following attributes: (1) extended residence in the vagina such that their use is not coitally dependent; (2) embody either single or combination anti-HIV microbicides; and (3) have favorable acceptability by women. The smart gel will spread well initially upon insertion, and then increase in physical integrity and remain in place for at least 24 hours. The intravaginal ring will deliver a constant dose of microbicide molecules continuously over a duration of one month or greater. Three new families of active ingredients will be developed and delivered by the new vehicles. These molecules target multiple steps in the HIV infection and replication pathway and include the dual acting pyrimidinediones (inhibit virus entry and reverse transcription), ISIS 5320 (inhibits CD4-gp120 mediated attachment) and the virus inactivating NCp7 inhibitors. Collectively, these active ingredients target both cell-free and cell-associated virus. Optimal formulation strategies employing either gels or rings will be designed and implemented. The proposed work scope integrates new basic science and technology, preclinical development and exploratory clinical development. The candidate novel microbicides will be optimized for activity, stability and potency against both wild type and drug-resistant viruses. Medicinal chemistry will continue to provide compounds with enhanced antiviral properties in single or combination products. The new microbicide science and technology will fill critical gaps in the field, and foster new delivery systems that are optimized with respect to vaginal deployment and drug delivery functions. Simultaneously, current knowledge and evaluation methods for acceptability of gels and rings will be expanded, and physical attributes of these vehicles will be designed to co-optimize both behavioral acceptability and biological functionality. Product development will progress in synchrony with the new scientific understanding of HIV neutralization mechanisms, delivery system biomaterials and functionality, microbicide product pharmacokinetics and pharmacodynamics, and human perception and acceptability. The set of novel new experimental methods and pharmacokinetic and pharmacodynamic models is intended to be translatable for widespread use in the microbicide pipeline.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2012	IMQUEST BIOSCIENCES, INC.	7340 EXECUTIVE WAY STE R	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	5	1/31/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2012 ( Subtotal = $1,080,708 )
2012	2012	IMQUEST BIOSCIENCES INC	7340 EXECUTIVE WAY	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	5	4/20/2012	NON-COMPETING CONTINUATION	$1,080,708
														Subtotal = $1,080,708

Issue Date FY: 2011 ( Subtotal = $1,265,859 )
2011	2011	IMQUEST BIOSCIENCES INC	7340 EXECUTIVE WAY	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	4	7/22/2011	NON-COMPETING CONTINUATION	$1,265,859
														Subtotal = $1,265,859

Issue Date FY: 2010 ( Subtotal = $1,578,326 )
2010	2010	IMQUEST BIOSCIENCES INC	7340 EXECUTIVE WAY	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	3	7/2/2010	NON-COMPETING CONTINUATION	$1,578,326
														Subtotal = $1,578,326

Issue Date FY: 2009 ( Subtotal = $1,389,746 )
2009	2009	IMQUEST BIOSCIENCES INC	7340 EXECUTIVE WAY	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	2	8/6/2009	NON-COMPETING CONTINUATION	$1,389,746
														Subtotal = $1,389,746

Issue Date FY: 2008 ( Subtotal = $1,374,317 )
2008	2008	IMQUEST BIOSCIENCES INC	7340 EXECUTIVE WAY	FREDERICK	MD	21704	FREDERICK	USA	Allergy and Infectious Diseases Research	000	1	6/27/2008	NEW	$1,374,317
														Subtotal = $1,374,317

Grand Total All Awards = $6,688,956

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic

Award Number: U19AI077289

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/27/2008

PERIOD OF PERFORMANCE END DATE: 05/31/2014

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer